
Roberto Fancellu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1128595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology, 2006, 66, 1717-1720.	1.5	1,579
2	Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain, 2008, 131, 2321-2331.	3.7	169
3	Reliability and validity of the International Cooperative Ataxia Rating Scale: A study in 156 spinocerebellar ataxia patients. Movement Disorders, 2006, 21, 699-704.	2.2	150
4	Plasma Homocysteine and I-DOPA Metabolism in Patients with Parkinson Disease. Clinical Chemistry, 2001, 47, 1102-1104.	1.5	98
5	Cognitive and affective status in mild hypothyroidism and interactions with l-thyroxine treatment. Acta Neurologica Scandinavica, 2004, 110, 59-66.	1.0	92
6	Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiology of Disease, 2006, 22, 1-9.	2.1	92
7	Longitudinal study of cognitive and psychiatric functions in spinocerebellar ataxia types 1 and 2. Journal of Neurology, 2013, 260, 3134-3143.	1.8	82
8	Spinocerebellar ataxia type 17 (SCA17): Oculomotor phenotype and clinical characterization of 15 Italian patients. Journal of Neurology, 2007, 254, 1538-1546.	1.8	78
9	Selfâ€rated health status in spinocerebellar ataxia—Results from a European multicenter study. Movement Disorders, 2010, 25, 587-595.	2.2	74
10	Spinocerebellar Ataxia Types 1, 2, 3 and 6: the Clinical Spectrum of Ataxia and Morphometric Brainstem and Cerebellar Findings. Cerebellum, 2012, 11, 155-166.	1.4	74
11	Depression comorbidity in spinocerebellar ataxia. Movement Disorders, 2011, 26, 870-876.	2.2	69
12	Peripheral Levels of BDNF and NGF in Primary Headaches. Cephalalgia, 2006, 26, 136-142.	1.8	63
13	Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson?s disease. The effect of dopaminergic treatment. Journal of Neural Transmission, 2004, 111, 1017-30.	1.4	58
14	Erythropoietin in Friedreich ataxia: No effect on frataxin in a randomized controlled trial. Movement Disorders, 2012, 27, 446-449.	2.2	57
15	An overview of the patient with ataxia. Journal of Neurology, 2005, 252, 511-518.	1.8	54
16	Ataxia with oculomotor apraxia type1 (AOA1): novel and recurrent aprataxin mutations, coenzyme Q10 analyses, and clinical findings in Italian patients. Neurogenetics, 2011, 12, 193-201.	0.7	46
17	Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 325-330.	1.8	42
18	Rare association of motor neuron disease and spinocerebellar ataxia type 2 (SCA2): a new case and review of the literature. Journal of Neurology, 2009, 256, 1926-1928.	1.8	42

Roberto Fancellu

#	Article	IF	CITATIONS
19	Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia. Brain, 2021, 144, 2310-2321.	3.7	38
20	Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Brain Research, 2007, 1176, 53-61.	1.1	34
21	Peripheral Markers of Apoptosis in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 1010, 675-678.	1.8	30
22	Long-Term Treatment with High-Dose Thiamine in Parkinson Disease: An Open-Label Pilot Study. Journal of Alternative and Complementary Medicine, 2015, 21, 740-747.	2.1	29
23	Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurological Sciences, 2001, 22, 49-50.	0.9	27
24	Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies. Scientific Reports, 2017, 7, 7831.	1.6	27
25	Digenic inheritance of STUB1 variants and TBP polyglutamine expansions explains the incomplete penetrance of SCA17 and SCA48. Genetics in Medicine, 2022, 24, 29-40.	1.1	24
26	Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. European Journal of Neuroscience, 2003, 17, 763-770.	1.2	23
27	CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 303-310.	0.9	20
28	Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia. Journal of Neurology, 2016, 263, 2170-2178.	1.8	18
29	Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson?s disease. Neurological Sciences, 2003, 24, 157-158.	0.9	16
30	Dopamine Receptor Agonists Mediate Neuroprotection in Malonate-Induced Striatal Lesion in the Rat. Experimental Neurology, 2002, 178, 301-305.	2.0	14
31	An open-label pilot study with high-dose thiamine in Parkinson′s disease. Neural Regeneration Research, 2016, 11, 406.	1.6	14
32	Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson?s disease. Journal of Neural Transmission, 2003, 110, 911-922.	1.4	13
33	Leber's Hereditary Optic Neuropathy: A Report on Novel mtDNA Pathogenic Variants. Frontiers in Neurology, 2021, 12, 657317.	1.1	13
34	Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. Neurological Sciences, 2003, 24, 180-181.	0.9	10
35	Challenges in Diagnosis and Treatment of Wernicke Encephalopathy. Nutrition in Clinical Practice, 2016, 31, 186-190.	1.1	10
36	Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. Brain Research, 2006, 1101, 145-150.	1.1	7

Roberto Fancellu

#	Article	IF	CITATIONS
37	Dopaminergic and Serotonergic Degeneration and Cortical [18 F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. Movement Disorders, 2021, 36, 2293-2302.	2.2	7
38	Immunological Reactivity against Neuronal and Non-Neuronal Antigens in Sporadic Adult-Onset Cerebellar Ataxia. European Neurology, 2009, 62, 356-361.	0.6	6
39	Lower limb areflexia without central and peripheral conduction abnormalities is highly suggestive of Gerstmann–StrÃ ¤ ssler–Scheinker disease Pro102Leu. Journal of the Neurological Sciences, 2011, 302, 85-88.	0.3	6
40	Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma. Functional Neurology, 0, , .	1.3	6
41	Paraneoplastic cerebellar ataxia associated with anti-Hu antibodies and benign ganglioneuroma. Functional Neurology, 2014, 29, 277-80.	1.3	6
42	Can long-term thiamine treatment improve the clinical outcomes of myotonic dystrophy type 1?. Neural Regeneration Research, 2016, 11, 1487.	1.6	4
43	Primary AL amyloidosis presenting as lower motor neuron disease. Journal of the Neurological Sciences, 2016, 364, 177-179.	0.3	3
44	Serial magnetic resonance study in super refractory status epilepticus: progressive involvement of striatum and pallidus is a possible predictive marker of negative outcome. Neurological Sciences, 2017, 38, 1513-1516.	0.9	3
45	Thiamine and dystonia 16. BMJ Case Reports, 2016, 2016, bcr-2016-216721.	0.2	2
46	Interoperability Standards for Data Sharing as a Basis to Fill in a Tailored EHR for Undiagnosed Rare Diseases. Studies in Health Technology and Informatics, 2021, 287, 114-118.	0.2	0